InvestorsHub Logo
Followers 1520
Posts 89014
Boards Moderated 5
Alias Born 05/09/2004

Re: Rory2 post# 18023

Monday, 07/24/2017 2:49:26 PM

Monday, July 24, 2017 2:49:26 PM

Post# of 27676
RCHA - "entered into a Support and Collaboration Agreement (the “Collaboration Agreement”) with Mega Bridge, Inc., a Nevada corporation to be renamed “Hypgen”) (“Hypgen”), to support Hypgen’s development of treatments for Parkinson’s Disease. Under the terms of the agreement, the Company will provide data, raw materials and advisory support to Hypgen to assist Hypgen with their development of treatments for Parkinson’s Disease and the associated regulatory approval process. In exchange, Hypgen will pay the Company $100,000 and issue the Company 15,000,000 shares of Hypgen common stock. The Company plans to dividend five million of these shares to its shareholders at such time as the Company completes the necessary corporate and regulatory requirements regarding payment of a dividend."
https://marketexclusive.com/rich-pharmaceuticals-inc-otcmktsrcha-files-an-8-k-entry-into-a-material-definitive-agreement-4/2017/07/

That DR is CEO of MEGA BRIDGE/HYPGEN's

I got it now

All the best

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.